Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26186467 | 1.00 | ANO1 (0.60) | ANO1ALDH1A1P2RX4JAK2TYK2 | |
| SCHEMBL30402922 | 0.86 | ANO1 (0.61) | ANO1ALDH1A1P2RX4SMN1; SMN2NPC1 | |
| SCHEMBL29029227 | 0.85 | ANO1 (0.58) | ANO1ALDH1A1P2RX4JAK2TYK2 | |
| SCHEMBL30368210 | 0.85 | ANO1 (0.65) | ANO1ALDH1A1P2RX4JAK2TYK2 | |
| SCHEMBL26186449 | 0.84 | ALDH1A1 (0.49) | ANO1ALDH1A1P2RX4SMN1; SMN2EGFR | |
| SCHEMBL30285633 | 0.84 | ALDH1A1 (0.49) | ANO1ALDH1A1P2RX4SMN1; SMN2EGFR | |
| SCHEMBL26186470 | 0.78 | P2RX4 (0.74) | ANO1ALDH1A1P2RX4SMN1; SMN2 | |
| SCHEMBL30285369 | 0.78 | P2RX4 (0.74) | ANO1ALDH1A1P2RX4SMN1; SMN2 | |
| SCHEMBL24173293 | 0.78 | SMN1; SMN2 (0.67) | ANO1ALDH1A1P2RX4JAK2TYK2 | |
| SCHEMBL30285888 | 0.77 | ANO1 (0.48) | ANO1ALDH1A1P2RX4SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | disclosed |